上海华奥泰生物

Shanghai Huaota Biopharmaceutical is a clinical-stage biotechnology company focused on the discovery and development of novel biologics, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs). As a subsidiary of Zhejiang Huahai Pharmaceutical, the company leverages its proprietary platforms to target high-unmet-need areas in oncology, autoimmune diseases, and ophthalmology. Its pipeline includes several assets in various stages of clinical development, such as HB0034 (anti-IL-36R) and HB0025 (PD-L1/VEGF bispecific). Huaota operates integrated R&D and manufacturing facilities in Shanghai to support its global clinical strategy. The company aims to provide high-quality, affordable innovative biologics to patients worldwide through internal innovation and strategic collaborations.